Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021

 

Upgrades

  • According to JonesTrading, the prior rating for Orchid Island Capital Inc ORC was changed from Sell to Hold. In the second quarter, Orchid Island Capital showed an EPS of $0.17, compared to $0.73 from the year-ago quarter. The current stock performance of Orchid Island Capital shows a 52-week-high of $6.22 and a 52-week-low of $4.80. Moreover, at the end of the last trading period, the closing price was at $5.03.
  • Goldman Sachs upgraded the previous rating for Allegion PLC ALLE from Neutral to Buy. For the second quarter, Allegion had an EPS of $1.32, compared to year-ago quarter EPS of $0.92. At the moment, the stock has a 52-week-high of $148.69 and a 52-week-low of $94.01. Allegion closed at $143.28 at the end of the last trading period.
  • For Rexnord Corp RXN, Goldman Sachs upgraded the previous rating of Neutral to Buy. For the second quarter, Rexnord had an EPS of $0.58, compared to year-ago quarter EPS of $0.47. The stock has a 52-week-high of $63.98 and a 52-week-low of $28.10. At the end of the last trading period, Rexnord closed at $62.75.
  • For CNO Financial Group Inc CNO, Piper Sandler upgraded the previous rating of Neutral to Overweight. CNO Finl Group earned $0.66 in the second quarter, compared to $0.55 in the year-ago quarter. The stock has a 52-week-high of $27.89 and a 52-week-low of $15.27. At the end of the last trading period, CNO Finl Group closed at $23.22.
  • According to National Bank Of Canada, the prior rating for Hudbay Minerals Inc HBM was changed from Sector Perform to Outperform. Hudbay Minerals earned $0.02 in the second quarter, compared to $0.15 in the year-ago quarter. The stock has a 52-week-high of $9.60 and a 52-week-low of $3.82. At the end of the last trading period, Hudbay Minerals closed at $5.89.
  • Oppenheimer upgraded the previous rating for Editas Medicine Inc EDIT from Perform to Outperform. Editas Medicine earned $0.81 in the second quarter, compared to $0.43 in the year-ago quarter. The stock has a 52-week-high of $99.95 and a 52-week-low of $27.01. At the end of the last trading period, Editas Medicine closed at $64.45.

See all analyst ratings upgrades.

 

Downgrades

  • According to Jefferies, the prior rating for Humanigen Inc HGEN was changed from Buy to Hold. In the second quarter, Humanigen showed an EPS of $1.20, compared to $0.79 from the year-ago quarter. The stock has a 52-week-high of $29.20 and a 52-week-low of $6.09. At the end of the last trading period, Humanigen closed at $7.97.
  • B of A Securities downgraded the previous rating for Cigna Corp CI from Buy to Underperform. Cigna earned $5.24 in the second quarter, compared to $5.81 in the year-ago quarter. The current stock performance of Cigna shows a 52-week-high of $272.81 and a 52-week-low of $158.84. Moreover, at the end of the last trading period, the closing price was at $213.95.
  • According to Wedbush, the prior rating for Apellis Pharmaceuticals Inc APLS was changed from Outperform to Neutral. In the second quarter, Apellis Pharmaceuticals showed an EPS of $2.72, compared to $1.57 from the year-ago quarter. The current stock performance of Apellis Pharmaceuticals shows a 52-week-high of $73.00 and a 52-week-low of $28.37. Moreover, at the end of the last trading period, the closing price was at $55.61.
  • Oppenheimer downgraded the previous rating for American Tower Corp AMT from Outperform to Perform. In the second quarter, American Tower showed an EPS of $2.73, compared to $2.07 from the year-ago quarter. The stock has a 52-week-high of $303.72 and a 52-week-low of $197.50. At the end of the last trading period, American Tower closed at $296.82.
  • Oppenheimer downgraded the previous rating for Crown Castle International Corp CCI from Outperform to Perform. Crown Castle Intl earned $1.71 in the second quarter, compared to $1.45 in the year-ago quarter. The current stock performance of Crown Castle Intl shows a 52-week-high of $204.62 and a 52-week-low of $146.15. Moreover, at the end of the last trading period, the closing price was at $192.46.
  • For Equinix Inc EQIX, Oppenheimer downgraded the previous rating of Outperform to Perform. Equinix earned $7.01 in the second quarter, compared to $6.35 in the year-ago quarter. The stock has a 52-week-high of $885.26 and a 52-week-low of $586.73. At the end of the last trading period, Equinix closed at $854.56.
  • BTIG downgraded the previous rating for Sumo Logic Inc SUMO from Buy to Neutral. Interestingly, in the second quarter, Sumo Logic's EPS was $0.11. At the moment, the stock has a 52-week-high of $46.37 and a 52-week-low of $15.80. Sumo Logic closed at $20.12 at the end of the last trading period.
  • According to Goldman Sachs, the prior rating for Colfax Corp CFX was changed from Buy to Neutral. In the second quarter, Colfax showed an EPS of $0.56, compared to $0.09 from the year-ago quarter. At the moment, the stock has a 52-week-high of $50.34 and a 52-week-low of $26.45. Colfax closed at $46.93 at the end of the last trading period.
  • National Bank Of Canada downgraded the previous rating for Agnico Eagle Mines Ltd AEM from Outperform to Sector Perform. Agnico Eagle Mines earned $0.69 in the second quarter, compared to $0.18 in the year-ago quarter. The stock has a 52-week-high of $89.23 and a 52-week-low of $54.66. At the end of the last trading period, Agnico Eagle Mines closed at $56.67.

See all analyst ratings downgrades.

 

Initiations

  • For First Solar Inc FSLR, Needham initiated coverage, by setting the current rating at Hold. In the second quarter, First Solar showed an EPS of $0.77, compared to $0.39 from the year-ago quarter. The stock has a 52-week-high of $112.50 and a 52-week-low of $59.52. At the end of the last trading period, First Solar closed at $98.89.
  • Truist Securities initiated coverage on Shift Technologies Inc SFT with a Buy rating. The price target for Shift Technologies is set to $12.00. Shift Technologies earned $0.41 in the second quarter, compared to $5.79 in the year-ago quarter. At the moment, the stock has a 52-week-high of $12.34 and a 52-week-low of $6.17. Shift Technologies closed at $8.04 at the end of the last trading period.
  • For U.S. Xpress Enterprises Inc USX, Raymond James initiated coverage, by setting the current rating at Market Perform. In the second quarter, U.S. Xpress Enterprises showed an EPS of $0.08, compared to $0.18 from the year-ago quarter. The current stock performance of U.S. Xpress Enterprises shows a 52-week-high of $12.33 and a 52-week-low of $6.18. Moreover, at the end of the last trading period, the closing price was at $8.66.
  • With a Market Perform rating, Cowen & Co. initiated coverage on Beyond Meat Inc BYND. The price target seems to have been set at $124.00 for Beyond Meat. In the second quarter, Beyond Meat showed an EPS of $0.31, compared to $0.02 from the year-ago quarter. At the moment, the stock has a 52-week-high of $221.00 and a 52-week-low of $99.86. Beyond Meat closed at $114.13 at the end of the last trading period.
  • SVB Leerink initiated coverage on Celldex Therapeutics Inc CLDX with an Outperform rating. The price target for Celldex Therapeutics is set to $68.00. For the second quarter, Celldex Therapeutics had an EPS of $0.34, compared to year-ago quarter EPS of $0.50. The stock has a 52-week-high of $56.13 and a 52-week-low of $11.44. At the end of the last trading period, Celldex Therapeutics closed at $53.76.
  • For Schneider National Inc SNDR, Raymond James initiated coverage, by setting the current rating at Market Perform. For the second quarter, Schneider National had an EPS of $0.60, compared to year-ago quarter EPS of $0.26. At the moment, the stock has a 52-week-high of $28.13 and a 52-week-low of $20.20. Schneider National closed at $22.27 at the end of the last trading period.
  • For Marten Transport Ltd MRTN, Raymond James initiated coverage, by setting the current rating at Market Perform. For the second quarter, Marten Transport had an EPS of $0.26, compared to year-ago quarter EPS of $0.33. The current stock performance of Marten Transport shows a 52-week-high of $19.08 and a 52-week-low of $14.79. Moreover, at the end of the last trading period, the closing price was at $15.47.
  • With an Outperform rating, Cowen & Co. initiated coverage on SunOpta Inc STKL. The price target seems to have been set at $15.00 for SunOpta. In the second quarter, SunOpta showed an EPS of $0.00, compared to $0.02 from the year-ago quarter. The current stock performance of SunOpta shows a 52-week-high of $17.07 and a 52-week-low of $6.30. Moreover, at the end of the last trading period, the closing price was at $9.28.
  • Alliance Global Partners initiated coverage on Arcimoto Inc FUV with a Buy rating. The price target for Arcimoto is set to $18.00. For the second quarter, Arcimoto had an EPS of $0.26, compared to year-ago quarter EPS of $0.15. The current stock performance of Arcimoto shows a 52-week-high of $36.80 and a 52-week-low of $5.10. Moreover, at the end of the last trading period, the closing price was at $12.14.
  • Berenberg initiated coverage on iStar Inc STAR with a Buy rating. The price target for iStar is set to $39.00. iStar earned $0.15 in the second quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $26.78 and a 52-week-low of $11.17. iStar closed at $26.24 at the end of the last trading period.
  • With a Market Perform rating, Cowen & Co. initiated coverage on Amedisys Inc AMED. The price target seems to have been set at $195.00 for Amedisys. In the second quarter, Amedisys showed an EPS of $1.69, compared to $1.34 from the year-ago quarter. The stock has a 52-week-high of $325.12 and a 52-week-low of $174.05. At the end of the last trading period, Amedisys closed at $183.01.
  • With an Outperform rating, Cowen & Co. initiated coverage on HCA Healthcare Inc HCA. The price target seems to have been set at $293.00 for HCA Healthcare. In the second quarter, HCA Healthcare showed an EPS of $4.37, compared to $3.23 from the year-ago quarter. At the moment, the stock has a 52-week-high of $261.80 and a 52-week-low of $114.38. HCA Healthcare closed at $258.26 at the end of the last trading period.
  • Cowen & Co. initiated coverage on Acadia Healthcare Co Inc ACHC with an Outperform rating. The price target for Acadia Healthcare Co is set to $79.00. For the second quarter, Acadia Healthcare Co had an EPS of $0.71, compared to year-ago quarter EPS of $0.54. The current stock performance of Acadia Healthcare Co shows a 52-week-high of $68.65 and a 52-week-low of $27.07. Moreover, at the end of the last trading period, the closing price was at $65.70.
  • Goldman Sachs initiated coverage on Kaiser Aluminum Corp KALU with a Sell rating. The price target for Kaiser Aluminum is set to $122.00. Kaiser Aluminum earned $1.00 in the second quarter, compared to $0.36 in the year-ago quarter. The current stock performance of Kaiser Aluminum shows a 52-week-high of $141.07 and a 52-week-low of $50.49. Moreover, at the end of the last trading period, the closing price was at $121.26.
  • Cowen & Co. initiated coverage on DaVita Inc DVA with a Market Perform rating. The price target for DaVita is set to $145.00. In the second quarter, DaVita showed an EPS of $2.64, compared to $1.95 from the year-ago quarter. The stock has a 52-week-high of $136.48 and a 52-week-low of $80.85. At the end of the last trading period, DaVita closed at $129.09.
  • Cowen & Co. initiated coverage on CareMax Inc CMAX with an Outperform rating. The price target for CareMax is set to $14.00. CareMax earned $0.26 in the second quarter, compared to $0.31 in the year-ago quarter. The stock has a 52-week-high of $15.91 and a 52-week-low of $6.53. At the end of the last trading period, CareMax closed at $8.48.
  • Cowen & Co. initiated coverage on Bright Health Group Inc BHG with an Outperform rating. The price target for Bright Health Gr is set to $14.00. Interestingly, in the second quarter, Bright Health Gr's EPS was $0.28. At the moment, the stock has a 52-week-high of $17.93 and a 52-week-low of $7.98. Bright Health Gr closed at $9.67 at the end of the last trading period.
  • Cowen & Co. initiated coverage on Agilon Health Inc AGL with an Outperform rating. The price target for Agilon Health is set to $44.00. In the second quarter, Agilon Health earned $0.79. At the moment, the stock has a 52-week-high of $44.83 and a 52-week-low of $26.50. Agilon Health closed at $31.51 at the end of the last trading period.
  • Cowen & Co. initiated coverage on Signify Health Inc SGFY with a Market Perform rating. The price target for Signify Health is set to $27.00. In the second quarter, Signify Health earned $0.00. The current stock performance of Signify Health shows a 52-week-high of $40.79 and a 52-week-low of $22.13. Moreover, at the end of the last trading period, the closing price was at $24.35.
  • With an Underperform rating, Cowen & Co. initiated coverage on Clover Health Investments Corp CLOV. The price target seems to have been set at $7.00 for Clover Health Investments. In the second quarter, Clover Health Investments earned $0.78. The current stock performance of Clover Health Investments shows a 52-week-high of $28.85 and a 52-week-low of $6.31. Moreover, at the end of the last trading period, the closing price was at $9.31.

See all analyst ratings initiations.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
▲▼
ticker
▲▼
name
▲▼
Price Target
▲▼
Upside/Downside
▲▼
Recommendation
▲▼
Firm
▲▼
Posted In: UpgradesDowngradesInitiationIntraday UpdateAnalyst RatingsBZI-Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!